# US 2024/0197222 A1 · Oral care flavour for improving happiness state and method of assessing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197222 A1
- Document ID: US20240197222A1
- Status: Published application
- Kind: A1
- Application number: 18/555,838
- Filed: 2022-05-30
- Published: 2024-06-20
- Earliest claimed: 2021-05-28
- Assignees: Givaudan SA
- Applicants: Givaudan SA
- Inventors: Giuliano GAETA; Alan Forbes PROVAN; Imogen Maria MATHEWS; Salla Katja Emilia PARKKINEN
- Web page: https://patentgrep.com/patent/US20240197222A1

## CPC

- A61B 5/0075: {by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy (A61B5/0071 takes precedence)}
- A61B 5/0036: {including treatment, e.g., using an implantable medical device, ablating, ventilating}
- A61B 5/1455: using optical sensors, e.g. spectral photometrical oximeters
- A61B 5/14551: {for measuring blood gases}
- A61B 5/14553: {specially adapted for cerebral tissue}
- A61B 5/165: {Evaluating the state of mind, e.g. depression, anxiety}
- A61B 5/4011: {Evaluating olfaction, i.e. sense of smell}
- A61B 5/4076: {Diagnosing or monitoring particular conditions of the nervous system}
- A61B 5/4836: {Diagnosis combined with treatment in closed-loop systems or methods (A61B5/0036 takes precedence)}
- A61B 5/4839: {combined with drug delivery}
- A61K 31/015: carbocyclic
- A61K 31/11: Aldehydes
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/222: with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/351: not condensed with another ring
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 36/534: Mentha (mint)
- A61K 36/73: Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K 36/752: Citrus, e.g. lime, orange or lemon
- A61K 36/899: Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61M 21/02: for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia (for massage A61H; electrotherapy A61N, e.g. applying alternating or intermittent electric currents for producing anaesthesia A61N1/36021)
- C11B 9/00: Essential oils; Perfumes
- C11B 9/0061: {compounds containing a six-membered aromatic ring not condensed with another ring}
- A61B 2503/12: Healthy persons not otherwise provided for, e.g. subjects of a marketing survey
- A61M 15/08: Inhaling devices inserted into the nose
- A61M 2021/0016: {by the smell sense}
- A61M 2205/3313: used specific wavelengths
- A61M 2230/20: Blood composition characteristics
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- C11B: PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES (drying-oils C09F)

## Abstract

The present disclosure relates to methods of assessing the ability of a test oral care flavour ingredient or a test oral care flavour composition to improve the happiness state of a human subject and of creating oral care flavour compositions having a positive happy effect on a human subject. It further relates to oral care flavour compositions for improving the happiness state of a human subject, to consumer products comprising such oral care flavour compositions, and to methods of improving the happiness state of a human subject.

## Claims

### Claim 1

A method of assessing the ability of a test oral care flavour ingredient or a test oral care flavour composition to improve the happiness state of a human subject, comprising the steps of:
a) measuring a base happiness state of one or more human test subject(s);
b) providing the test oral care flavour ingredient or the test oral care flavour composition to the human test subject(s) for oral application;
c) measuring a resulting happiness state of the human test subject(s); and
d) determining a difference between the resulting happiness state and the base happiness state for the human test subject(s);
wherein the base happiness state and the resulting happiness state are measured by functional Near Infrared Spectroscopy (fNIRS) of the human test subject(s)' left brain hemisphere, right brain hemisphere, and full brain;
wherein the test oral care flavour ingredient or the test oral care flavour composition is able to improve the happiness state of the human subject if at least one out of the following eight conditions A1 through A8 is met:
A1. Channel 14 shows a statistically significant difference of Total Hb 0-10 seconds after the oral application;
A2. Channel 15 shows a statistically significant difference of Total Hb 0-10 seconds after the oral application;
A3. Channel 18 shows a statistically significant difference of Total Hb 0-10 seconds after the oral application;
A4. Channel 19 shows a statistically significant difference of Total Hb 0-10 seconds after the oral application;
A5. Channel 1 shows a statistically significant difference of Total Hb 0-10 seconds after the oral application;
A6. Channel 3 shows a statistically significant difference of Total Hb 0-10 seconds after the oral application;
A7. Channel 4 shows a statistically significant difference of Total Hb 0-10 seconds after the oral application;
A8. Channel 5 shows a statistically significant difference of Total Hb 0-10 seconds after the oral application;
wherein Total Hb is the amount of total haemoglobin measured, and
wherein Channels 1 to 8 and 11 are located in the left brain hemisphere, Channels 9 and 12 are located on the midline, and Channels 10 and 13 to 20 are located in the right brain hemisphere.

### Claim 2 (depends on 1)

The method of claim 1, wherein the test oral care flavour ingredient or the test oral care flavour composition is provided to the human test subject(s) as part of a toothpaste a mouthwash, a breath spray or a dental floss.

### Claim 3 (depends on 1)

The method of claim 1, wherein further at least one, more preferably at least two, out of the following nine conditions B1 through B9 is met:
B1. Channel 14 shows a statistically significant difference of Oxy Hb 0-10 seconds after the oral application;
B2. Channel 16 shows a statistically significant difference of Oxy Hb 0-10 seconds after the oral application;
B3. Channel 18 shows a statistically significant difference of Oxy Hb 0-10 seconds after the oral application;
B4. Channel 20 shows a statistically significant difference of Oxy Hb 0-10 seconds after the oral application;
B5. Channel 2 shows a statistically significant difference of Oxy Hb 0-10 seconds after the oral application;
B6. Channel 3 shows a statistically significant difference of Oxy Hb 0-10 seconds after the oral application;
B7. Channel 4 shows a statistically significant difference of Oxy Hb 0-10 seconds after the oral application;
B8. Channel 5 shows a statistically significant difference of Oxy Hb 0-10 seconds after the oral application;
B9. Channel 6 shows a statistically significant difference of Oxy Hb 0-10 seconds after the oral application;
wherein Oxy Hb is the amount of oxygenated haemoglobin measured.

### Claim 4 (depends on 1)

The method of claim 1, wherein further at least one, more preferably at least two, out of the following eight conditions C1 through C8 is met:
C1. Channel 16 shows a statistically significant difference of Total Hb 5-10 seconds after the oral application;
C2. Channel 19 shows a statistically significant difference of Total Hb 5-10 seconds after the oral application;
C3. Channel 20 shows a statistically significant difference of Total Hb 5-10 seconds after the oral application;
C4. Channel 1 shows a statistically significant difference of Total Hb 5-10 seconds after the oral application;
C5. Channel 4 shows a statistically significant difference of Total Hb 5-10 seconds after the oral application;
C6. Channel 6 shows a statistically significant difference of Total Hb 5-10 seconds after the oral application;
C7. Channel 9 shows a statistically significant difference of Total Hb 5-10 seconds after the oral application;
C8. Channel 12 shows a statistically significant difference of Total Hb 5-10 seconds after the oral application.

### Claim 5 (depends on 1)

A method of creating an oral care flavour composition having effect of improving the happiness of a human subject, comprising the steps of:
(i) creating a test oral care flavour composition;
(ii) assessing the ability of the test oral care flavour composition to improve the happiness state of a human subject according to the method of claim 1, and
(iii) adjusting, if necessary, the test oral care flavour composition by adding and/or removing at least one oral care flavour ingredient and/or increasing and/or reducing the concentration of at least one oral care flavour ingredient until the oral care flavour composition is found to improve the happiness state of the human subject.

### Claim 6 (depends on 5)

The method of claim 5, wherein, in step (iii), at least one HMP oral care flavour ingredient is added to the test oral care flavour composition and/or at least one HMR oral care flavour ingredient is added to the test oral care flavour composition and/or at least one HMI oral care flavour ingredient is added to the test oral care flavour composition and/or at least one INV oral care flavour ingredient is removed from the test oral care flavour composition and/or at least one REL oral care flavour ingredient is removed from the test oral care flavour composition and/or the concentration of at least one HMP and/or HMR and/or HMI oral care flavour ingredient is increased and/or the concentration of at least one INV and/or REL oral care flavour ingredient is reduced, wherein
the HMP oral care flavour ingredients are selected from the group consisting of fruity-strawberry ingredients, fruity-raspberry ingredients, fruity-apple ingredients, fruity-banana ingredients, floral-freesia ingredients, floral-lily of the valley ingredients, animalic-butyric ingredients, acetic acid, and mixtures thereof;
the HMR oral care flavour ingredients are selected from the group consisting of fruity-pineapple ingredients, fruity-peach ingredients, herbal-spearmint ingredients, lemon oil, lemon oil reconstitutions, and mixtures thereof;
the HMI oral care flavour ingredients are selected from the group consisting of citrus-orange ingredients, spicy-cinnamon ingredients, floral-jasmine ingredients, cooling ingredients, aromatic-wintergreen ingredients, lime terpenes, lime terpeneless, and mixtures thereof;
the INV oral care flavour ingredients are selected from the group consisting of citrus-lime ingredients (excluding lime terpenes and lime terpeneless), citrus-mandarin ingredients, citrus-grapefruit ingredients, spicy-pepper ingredients, spicy-clove ingredients, herbal-rosemary ingredients, green-grass ingredients, woody-resinous ingredients, herbal-coniferous ingredients, bergamot oils, 3,7-dimethylocta-1,6-dien-3-yl acetate (linalyl acetate), 3,7-dimethylocta-1,6-dien-3-yl 2-methylpropanoate (linalyl iso butyrate), (E)-3,7-dimethylocta-2,6-dienal (citral), lemongrass, Litsea cubeba oils, and mixtures thereof; and
the REL oral care flavour ingredients are selected from the group consisting of sweet-vanilla ingredients, sweet-coconut ingredients, sweet-cooked sugar ingredients, fruity-passionfruit ingredients, herbal-thyme ingredients, sage oils and reconstitutions, clary sage oils and reconstitutions, camomile oils and reconstitutions, lavender oils and reconstitutions, and mixtures thereof.

### Claim 7

An oral care flavour composition for improving the happiness state of a human subject, the oral care flavour composition comprising:
a) at least one HMP oral care flavour ingredient;
b) at least about 15% by weight in total of HMP and/or HMI and/or HMR oral care flavour ingredients;
c) optionally up to about 85% by weight in total of other oral care flavour ingredients, provided the following conditions are met:
(c1) PEPPERMINTs+INVs<75%
(c2) HMPs+HMIs>RELs
(c3) HMPs+HMRs>INVs
(c4) HMPs/(HMPs+RELs+INVs)≥0.3
wherein
(i) all percentages are based on total weight of the oral care flavour ingredients constituting the oral care flavour composition;
(ii) HMPs indicates the sum of percentages of HMP oral care flavour ingredients; HMIs indicates the sum of percentages of HMI oral care flavour ingredients; HMRs indicates the sum of percentages of HMR oral care flavour ingredients; PEPPERMINTs indicates the sum of percentages of PEPPERMINT oral care flavour ingredients; INVs indicates the sum of percentages of INV oral care flavour ingredients; and RELs indicates the sum of percentages of REL oral care flavour ingredients;
(iii) the symbol ≥ indicates at least equal to;
(iv) the HMP oral care flavour ingredients are selected from the group consisting of fruity-strawberry ingredients, fruity-raspberry ingredients, fruity-apple ingredients, fruity-banana ingredients, floral-freesia ingredients, floral-lily of the valley ingredients, animalic-butyric ingredients, acetic acid, and mixtures thereof;
(v) the HMI oral care flavour ingredients are selected from the group consisting of citrus-orange ingredients, spicy-cinnamon ingredients, floral-jasmine ingredients, cooling ingredients, aromatic-wintergreen ingredients, lime terpenes, lime terpeneless, and mixtures thereof;
(vi) the HMR oral care flavour ingredients are selected from the group consisting of fruity-pineapple ingredients, fruity-peach ingredients, herbal-spearmint ingredients, lemon oil, lemon oil reconstitutions, and mixtures thereof;
(vii) the PEPPERMINT oral care flavour ingredients have a peppermint organoleptic attribute;
(viii) the INV oral care flavour ingredients are selected from the group consisting of citrus-lime ingredients (excluding lime terpenes and lime terpeneless), citrus-mandarin ingredients, citrus-grapefruit ingredients, spicy-pepper ingredients, spicy-clove ingredients, herbal-rosemary ingredients, green-grass ingredients, woody-resinous ingredients, herbal-coniferous ingredients, bergamot oils, 3,7-dimethylocta-1,6-dien-3-yl acetate (linalyl acetate), 3,7-dimethylocta-1,6-dien-3-yl 2-methylpropanoate (linalyl iso butyrate), (E)-3,7-dimethylocta-2,6-dienal (citral), lemongrass, Litsea cubeba oils, and mixtures thereof; and
(ix) the REL oral care flavour ingredients are selected from the group consisting of sweet-vanilla ingredients, sweet-coconut ingredients, sweet-cooked sugar ingredients, fruity-passionfruit ingredients, herbal-thyme ingredients, sage oils and reconstitutions, clary sage oils and reconstitutions, camomile oils and reconstitutions, lavender oils and reconstitutions, and mixtures thereof.

### Claim 8 (depends on 7)

The oral care flavour composition of claim 7, comprising at least about 17%, more preferably at least about 20%, by weight in total of HMP and/or HMI and/or HMR oral care flavour ingredients.

### Claim 9 (depends on 7)

The oral care flavour composition of claim 7, comprising at least one HMP and/or HMI and/or HMR oral care flavour ingredient selected from one or more of the following groups:
one or more fruity-strawberry ingredients selected from the group consisting of benzyl 3-phenylprop-2-enoate (benzyl cinnamate), ethyl butanoate (ethyl butyrate), ethyl 2-methylpropionate (ethyl isobutyrate), ethyl 3-phenylprop-2-enoate (ethyl cinnamate), methyl 3-phenylprop-2-enoate (methyl cinnamate), ethyl 3-phenyloxirane-2-carboxylate (ethyl phenyl glycidate), ethyl 3-methyl-3-phenyloxirane-2-carboxylate (ethyl methyl phenyl glycidate), 2-phenylethyl butanoate (phenyl ethyl butyrate), benzyl butanoate (benzyl butyrate), ethyl 3-methylbutanoate (ethyl isovalerate), and mixtures thereof;
one or more fruity-raspberry ingredients selected from the group consisting of 4-(4-hydroxyphenyl)butan-2-one (raspberry ketone), methyoxy phenyl butanone, and mixtures thereof,
one or more fruity-apple ingredients selected from the group consisting of ethyl 2-methylbutanoate (ethyl 2-methyl butyrate), ethyl 3-oxobutanoate (ethyl aceto acetate), ethyl 2-methylpentanoate (manzanate), (Z)-hex-3-enyl acetate (cis-3-hexenyl acetate), (E)-2-hexenal (trans-2-hexenal), diethyl propanedioate (diethyl malonate), [(E)-hex-2-enyl] acetate (trans-2-hexenyl acetate), and mixtures thereof;
one or more fruity-banana ingredients selected from the group consisting of pentyl propanoate (amyl propionate), 3-methylbutyl 3-methylbutanoate (iso amyl iso valerate), 6-methylhept-5-en-2-one (methyl heptenone), 3-methylbutyl butanoate (iso amyl butyrate), 3-methylbutyl acetate (iso amyl acetate), pentyl butanoate (amyl butyrate), butyl acetate, 2-methylpropyl acetate (iso butyl acetate), and mixtures thereof;
one or more floral-freesia ingredients selected from the group consisting of 3,7-dimethylocta-1,6-dien-3-ol (linalool), 2-(4-methyl-1-cyclohex-3-enyl)propan-2-yl acetate (terpinyl acetate), 2-(4-methyl-1-cyclohex-3-enyl)propan-2-ol (terpineol alpha), 3,7-dimethylocta-1,6-dien-3-yl (E)-3-phenylprop-2-enoate (linalyl cinnamate), and mixtures thereof;
one or more floral-lily of the valley ingredients selected from the group consisting of 7-hydroxy-3,7-dimethyloctanal (hydroxycitronellal), 2-methyl-3-(4-propan-2-ylphenyl) propanal (cyclamen aldehyde), 3-(1,3-benzodioxol-5-yl)-2-methylpropanal (tropional), 2,6-dimethylhept-5-enal (melonal), and mixtures thereof;
one or more animalic-butyric ingredients selected from the group consisting of butanoic acid (butyric acid), octanoic acid, 2-methylbutanoic acid (2 methyl butyric acid), hexanoic acid (caproic acid), and mixtures thereof.
one or more citrus-orange ingredients selected from the group consisting of orange oil, orange terpenes, and mixtures thereof;
one or more spicy-cinnamon ingredients selected from the group consisting of cassia oils, 3-phenylprop-2-enal (cinnamic aldehyde), 2-methyl-3-phenylprop-2-enal (methyl cinnamic aldehyde), and mixtures thereof;
one or more cooling ingredients selected from the group consisting of N-(4-cyanomethylphenyl) p-menthane carboxamide (Evercool 180), 2-isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl)cyclohexane carboxamide (Evercool 190), 3-(5-methyl-2-propan-2-ylcyclohexyl)oxypropane-1,2-diol (Coolact P), (1R,2R,5S)-5-methyl-2-prop-1-en-2-yl-cyclohexan-1-ol (Coolact 10), ethyl 2-[[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexane-carbonyl]amino]acetate (WS-5), (1R,2S,5R)—N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide (WS-12), N-ethyl-5-methyl-2-propan-2-ylcyclo-hexane-1-carboxamide (WS-3), N,2,3-trimethyl-2-propan-2-ylbutanamide (WS-23), (E)-3-benzo(d)[1,3]dioxol-5-yl)-N,N-diphenylacrylamide (Icool MC6), 2-(p-tolyloxy)-N-(1H-pyrazol-5-yl)-N-((thiophen-2-yl)methyl)acetamide (Freezestorm), [(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl] 2-hydroxypropanoate (Frescolat ML), 2-isopropyl-5-methylcyclohexyloxycarbonyloxy-2-hydroxypropane (Frescolat MGC), 2-hydroxypropyl (5-methyl-2-propan-2-ylcyclohexyl) carbonate (Frescolat MPC), 9-Methyl-6-(1-methylethyl)-1,4-dioxaspiro-[4,5]decan-2-methanol (Frescolat MGA), menthyl lactate, mono-menthyl succinate, menthyl methyl ether, (2E)-3-(1,3-benzodioxol-5-yl)-N,N-diphenylacrylamide (iCool MC 6), 1-methyl-3-hydroxybutyrate, 2-{[5-methyl-2-(propan-2-yl)cyclohexyl]oxy}ethanol (Coolact 5), isomeric mix of 2-(2-hydroxypropan-2-yl)-5-methylcyclohexan-1-ol (Coolact 38D), and mixtures thereof,
one or more aromatic-wintergreen ingredients selected from the group consisting of ethyl 2-hydroxybenzoate (ethyl salicylate), methyl 2-hydroxybenzoate (methyl salicylate), wintergreen oil, and mixtures thereof;
one or more fruity-pineapple ingredients selected from the group consisting of pentyl hexanoate (amyl caproate), prop-2-enyl 3-cyclohexylpropanoate (allyl cyclohexyl propionate), 3-methylbutyl hexanoate (isoamyl caproate), methyl hexanoate, ethyl hexanoate, ethyl heptanoate, 2-phenylethyl 2-methylpropanoate (phenyl ethyl isobutyrate), prop-2-enyl propanoate (allyl propionate), and mixtures thereof;
one or more fruity-peach ingredients selected from the group consisting of 5-heptyldihydrofuran-2(3H)-one (undecalactone gamma), 5-hexyloxolan-2-one (decalactone gamma), 5-octyloxolan-2-one (dodecalatone gamma), 6-heptyloxan-2-one (dodecalatone delta), and mixtures thereof; and
one or more herbal-spearmint ingredients selected from the group consisting of spearmint oils, (1R,5S)-2-methyl-5-prop-1-en-2-ylcyclohex-2-en-1-ol and (1R,5R)-2-methyl-5-prop-1-en-2-ylcyclohex-2-en-1-ol (trans- and cis-carveol) and (5R)-2-methyl-5-prop-1-en-2-ylcyclohex-2-en-1-one (L-Carvone), and mixtures thereof.

### Claim 10 (depends on 7)

The oral care flavour composition of claim 7, wherein PEPPERMINTs+INVs<70%, more preferably PEPPERMINTs+INVs<65%, and most preferably PEPPERMINTs+INVs<60%.

### Claim 11 (depends on 7)

The oral care flavour composition of claim 7, wherein HMPs/(HMPs+RELs+INVs)≥0.35, more preferably HMPs/(HMPs+RELs+INVs)≥0.40, and most preferably HMPs/(HMPs+RELs+INVs)≥0.45.

### Claim 12 (depends on 7)

A consumer product comprising the oral care flavour composition of claim 7.

### Claim 13 (depends on 7)

A method of improving the happiness state of a human subject, comprising the step of providing an effective amount of the oral care flavour composition of claim 7 to the human subject.

### Claim 14

A method of using an oral care flavour ingredient in improving the happiness state of a human subject, wherein the oral care flavour ingredient is selected from the group consisting of:
one or more fruity-strawberry ingredients selected from the group consisting of benzyl 3-phenylprop-2-enoate (benzyl cinnamate), ethyl butanoate (ethyl butyrate), ethyl 2-methylpropionate (ethyl isobutyrate), ethyl 3-phenylprop-2-enoate (ethyl cinnamate), methyl 3-phenylprop-2-enoate (methyl cinnamate), ethyl 3-phenyloxirane-2-carboxylate (ethyl phenyl glycidate), ethyl 3-methyl-3-phenyloxirane-2-carboxylate (ethyl methyl phenyl glycidate), 2-phenylethyl butanoate (phenyl ethyl butyrate), benzyl butanoate (benzyl butyrate), ethyl 3-methylbutanoate (ethyl isovalerate), and mixtures thereof;
one or more fruity-raspberry ingredients selected from the group consisting of 4-(4-hydroxyphenyl)butan-2-one (raspberry ketone), methyoxy phenyl butanone, and mixtures thereof,
one or more fruity-apple ingredients selected from the group consisting of ethyl 2-methylbutanoate (ethyl 2-methyl butyrate), ethyl 3-oxobutanoate (ethyl aceto acetate), ethyl 2-methylpentanoate (manzanate), (Z)-hex-3-enyl acetate (cis-3-hexenyl acetate), (E)-2-hexenal (trans-2-hexenal), diethyl propanedioate (diethyl malonate), [(E)-hex-2-enyl] acetate (trans-2-hexenyl acetate), and mixtures thereof;
one or more fruity-banana ingredients selected from the group consisting of pentyl propanoate (amyl propionate), 3-methylbutyl 3-methylbutanoate (iso amyl iso valerate), 6-methylhept-5-en-2-one (methyl heptenone), 3-methylbutyl butanoate (iso amyl butyrate), 3-methylbutyl acetate (iso amyl acetate), pentyl butanoate (amyl butyrate), butyl acetate, 2-methylpropyl acetate (iso butyl acetate), and mixtures thereof;
one or more floral-freesia ingredients selected from the group consisting of 3,7-dimethylocta-1,6-dien-3-ol (linalool), 2-(4-methyl-1-cyclohex-3-enyl)propan-2-yl acetate (terpinyl acetate), 2-(4-methyl-1-cyclohex-3-enyl)propan-2-ol (terpineol alpha), 3,7-dimethylocta-1,6-dien-3-yl (E)-3-phenylprop-2-enoate (linalyl cinnamate), and mixtures thereof;
one or more floral-lily of the valley ingredients selected from the group consisting of 7-hydroxy-3,7-dimethyloctanal (hydroxycitronellal), 2-methyl-3-(4-propan-2-ylphenyl) propanal (cyclamen aldehyde), 3-(1,3-benzodioxol-5-yl)-2-methylpropanal (tropional), 2,6-dimethylhept-5-enal (melonal), and mixtures thereof;
one or more animalic-butyric ingredients selected from the group consisting of butanoic acid (butyric acid), octanoic acid, 2-methylbutanoic acid (2 methyl butyric acid), hexanoic acid (caproic acid), and mixtures thereof.
one or more citrus-orange ingredients selected from the group consisting of orange oil, orange terpenes, and mixtures thereof;
one or more spicy-cinnamon ingredients selected from the group consisting of cassia oils, 3-phenylprop-2-enal (cinnamic aldehyde), 2-methyl-3-phenylprop-2-enal (methyl cinnamic aldehyde), and mixtures thereof;
one or more cooling ingredients selected from the group consisting of N-(4-cyanomethylphenyl) p-menthane carboxamide (Evercool 180), 2-isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl)cyclohexane carboxamide (Evercool 190), 3-(5-methyl-2-propan-2-ylcyclohexyl)oxypropane-1,2-diol (Coolact P), (1R,2R,5S)-5-methyl-2-prop-1-en-2-yl-cyclohexan-1-ol (Coolact 10), ethyl 2-[[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclo-hexanecarbonyl]amino]acetate (WS-5), (1R,2S,5R)—N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide (WS-12), N-ethyl-5-methyl-2-propan-2-yl-cyclohexane-1-carboxamide (WS-3), N,2,3-trimethyl-2-propan-2-ylbutanamide (WS-23), (E)-3-benzo(d)[1,3]dioxol-5-yl)-N,N-diphenylacrylamide (Icool MC6), 2-(p-tolyloxy)-N-(1H-pyrazol-5-yl)-N-((thiophen-2-yl)methyl)acetamide (Freezestorm), [(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl] 2-hydroxypropanoate (Frescolat ML), 2-isopropyl-5-methylcyclohexyloxycarbonyloxy-2-hydroxypropane (Frescolat MGC), 2-hydroxypropyl (5-methyl-2-propan-2-ylcyclohexyl) carbonate (Frescolat MPC), 9-Methyl-6-(1-methyl-ethyl)-1,4-dioxaspiro-[4,5]decan-2-methanol (Frescolat MGA), menthyl lactate, mono-menthyl succinate, menthyl methyl ether, (2E)-3-(1,3-benzodioxol-5-yl)-N,N-diphenyl-acrylamide (iCool MC 6), 1-methyl-3-hydroxybutyrate, 2-{[5-methyl-2-(propan-2-yl)cyclohexyl]oxy}ethanol (Coolact 5), isomeric mix of 2-(2-hydroxypropan-2-yl)-5-methylcyclohexan-1-ol (Coolact 38D), and mixtures thereof,
one or more aromatic-wintergreen ingredients selected from the group consisting of ethyl 2-hydroxybenzoate (ethyl salicylate), methyl 2-hydroxybenzoate (methyl salicylate), wintergreen oil, and mixtures thereof:
one or more fruity-pineapple ingredients selected from the group consisting of pentyl hexanoate (amyl caproate), prop-2-enyl 3-cyclohexylpropanoate (allyl cyclohexyl propionate), 3-methylbutyl hexanoate (isoamyl caproate), methyl hexanoate, ethyl hexanoate, ethyl heptanoate, 2-phenylethyl 2-methylpropanoate (phenyl ethyl isobutyrate), prop-2-enyl propanoate (allyl propionate), and mixtures thereof;
one or more fruity-peach ingredients selected from the group consisting of 5-heptyldihydrofuran-2(3H)-one (undecalactone gamma), 5-hexyloxolan-2-one (decalactone gamma), 5-octyloxolan-2-one (dodecalatone gamma), 6-heptyloxan-2-one (dodecalatone delta), and mixtures thereof; and
one or more herbal-spearmint ingredients selected from the group consisting of spearmint oils, (1R,5S)-2-methyl-5-prop-1-en-2-ylcyclohex-2-en-1-ol and (1R,5R)-2-methyl-5-prop-1-en-2-ylcyclohex-2-en-1-ol (trans- and cis-carveol) and (5R)-2-methyl-5-prop-1-en-2-ylcyclohex-2-en-1-one (L-Carvone), and mixtures thereof.
